Area of research
Genetics · Hematology
Research interest
Research interests include Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Eosinophilic Disorders and Syndromes, and Acute Myeloid Leukemia Research.
Classical JAK2V617F+ Myeloproliferative Neoplasms emergence and development based on real life incidence and mathematical modeling
Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencing
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.
Classical Myelo-Proliferative Neoplasms emergence and development based on real life incidence and mathematical modeling
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis.
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
Clinical Features and Genomic Landscape of Myeloproliferative Neoplasm (MPN) Patients with Autoimmune and Inflammatory Diseases (AID)
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
p53 activation during ribosome biogenesis regulates normal erythroid differentiation
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of <i>ASXL1</i> mutations: a FIM study
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Multistage hematopoietic stem cell regulation in the mouse: A combined biological and mathematical approach.
p53 activation during ribosome biogenesis regulates normal erythroid differentiation
Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patients.